| C09DA03 |
Valsartan, Hydrochlorothiazide |
Suvartar H |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
Sandoz d.d., Словения |
1 |
tabl |
- |
6.71 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1704/27.11.2012 г.; НСР-1326/03.10.2013; НСР-5159/27.11.2014 |
02.04.2016 |
|
|
Активен |
3408 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valsalen H |
Film coated tablet |
160 mg/12,5 mg |
mg |
28 |
Екофарм Груп АД, България |
1 |
tabl |
- |
17.92 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
HCР-226/21.06.2013.; НСР-16791/20.09.2018 |
02.11.2018 |
|
|
Активен |
1968 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valsalen H |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
Екофарм Груп АД, България |
1 |
tabl |
- |
13.42 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
HCР-226/21.06.2013.; НСР-16792/20.09.2018 |
02.11.2018 |
|
|
Активен |
1969 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valsarcon-Co |
Film coated tablet |
160 mg/12,5 mg |
|
30 |
Фармаконс АД, България |
1 |
tabl |
- |
19.19 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-11667/10.02.2017; НСР-15667/17.05.2018 |
02.06.2018 |
|
|
Активен |
15595 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
VALSAVIL COMP |
Film coated tablet |
160 mg/ 12,5 mg |
mg |
30 |
Stada Arzneimittel AG, Германия |
1 |
tabl |
- |
9.83 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 172/ 31.05.2011; НСР-2507/24.01.2014; НСР-12579/05.05.2017 |
02.06.2017 |
08.09.2012 |
|
Активен |
2475 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
VALSOL PLUS |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
Инбиотех ООД, България |
1 |
tabl |
- |
7.45 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-4559/03.09.2014 |
02.04.2016 |
|
|
Активен |
3161 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valtensin Plus |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
Actavis Group PTC ehf., Исландия |
1 |
tabl |
- |
8.7 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№25/03.08.2009; КЦРР-2672/20.03.2013 г.; НСР-6684/09.07.2015.; КП-1/03.01.2018 и НСР-14175/13.10.2017 |
02.02.2018 |
08.09.2012 |
|
Активен |
1802 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valtensin Plus |
Film coated tablet |
320 mg/12,5 mg |
mg |
28 |
Actavis Group PTC ehf., Исландия |
1 |
tabl |
- |
17.17 |
0.58575 |
16.4 |
50% |
8.2 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1104/02.08.2012 г.; НСР-3277/24.04.2014; НСР-13645/01.09.2017 |
02.10.2017 |
08.09.2012 |
|
Активен |
2752 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valtensin Plus |
Film coated tablet |
320 mg/25 mg |
mg |
28 |
Actavis Group PTC ehf., Исландия |
1 |
tabl |
- |
17.17 |
0.61321 |
17.17 |
50% |
8.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-958/16.07.2012 г.; НСР-3324/24.04.2014; НСР-13644/01.09.2017 |
02.10.2017 |
08.09.2012 |
|
Активен |
2751 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Valtensin Plus |
Film coated tablet |
160 mg/ 12,5 mg |
|
28 |
Actavis Group PTC ehf., Исландия |
1 |
tabl |
- |
10.82 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№25/03.08.2009; КЦРР-2672/20.03.2013 г.; НСР-2517/24.01.2014; НСР-2804/17.02.2014 |
02.06.2017 |
08.09.2012 |
|
Активен |
2476 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
VALZAP H |
Film coated tablet |
160 mg/ 12,5 mg |
mg |
28 |
Zentiva k.s., Чешка република |
1 |
tabl |
- |
9.78 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 70/ 19.04.2010; № 119/10.11.2010; HCР-421/03.07.2013; НСР-7110/15.09.2015; НСР-10941/17.11.2016 |
02.06.2017 |
08.09.2012 |
|
Активен |
278 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Vanatex HCT |
Film coated tablet |
160 mg/25 mg |
mg |
28 |
Pharmaceutical Works Polpharma S.A. (PL), Полша |
1 |
tabl |
- |
19.03 |
0.23964 |
6.71 |
50% |
3.36 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1724/28.11.2012 г.; НСР-1084/02.09.2013; НСР-5464/16.01.2015; НСР-11171/08.12.2016 |
02.01.2017 |
|
|
Заличен |
3524 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Vanatex HCT |
Film coated tablet |
160 mg/12,5 mg |
mg |
28 |
Pharmaceutical Works Polpharma S.A. (PL), Полша |
1 |
tabl |
- |
16.56 |
0.33475 |
9.37 |
50% |
4.69 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1724/28.11.2012 г; НСР-1084/02.09.2013; НСР-5283/ 18.12.2014.; НСР-11171/08.12.2016 |
02.01.2017 |
|
|
Заличен |
3477 |
| C09DA03 |
Valsartan, Hydrochlorothiazide |
Vanatex HCT |
Film coated tablet |
80 mg/12,5 mg |
mg |
28 |
Pharmaceutical Works Polpharma S.A. (PL), Полша |
1 |
tabl |
- |
11.45 |
0.20925 |
5.86 |
50% |
2.93 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1724/28.11.2012 г.; НСР-1084/02.09.2013; НСР-3611/23.05.2014; НСР-11171/08.12.2016 |
02.01.2017 |
|
|
Заличен |
2818 |
| C09DA04 |
Irbesartan/ Hydrochlorothiazide |
C09DA04 Irbesartan/ Hydrochlorothiazide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C09DA04 |
Irbesartan and diuretics |
Co-Irbec |
Tablet |
300 mg/12.5 |
mg |
28 |
МС Фарма АД, България |
1 |
tabl |
- |
56.33 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-9949/29.07.2016 |
02.11.2018 |
|
|
Активен |
15328 |
| C09DA04 |
Irbesartan and diuretics |
Co-Irbec |
Tablet |
150mg/12.5 |
mg |
28 |
МС Фарма АД, България |
1 |
tabl |
- |
43.33 |
0.24758 |
6.93 |
50% |
3.46 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-9950/29.07.2016 |
02.07.2018 |
|
|
Активен |
15327 |
| C09DA04 |
Irbesartan and diuretics |
Co-Irbesan |
Film coated tablet |
300 mg/12,5 mg |
mg |
28 |
Нобел Фарма ЕООД, България |
1 |
tabl |
- |
33.47 |
0.32767 |
9.17 |
50% |
4.58 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-2914/20.03.2013. |
02.11.2018 |
|
|
Активен |
1779 |
| C09DA04 |
Irbesartan and diuretics |
Co-Irbesan |
Film coated tablet |
150 mg/12,5 mg |
mg |
28 |
Нобел Фарма ЕООД, България |
1 |
tabl |
- |
20.36 |
0.24758 |
6.93 |
50% |
3.46 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-2914/20.03.2013. |
02.07.2018 |
|
|
Активен |
1778 |
| C09DA04 |
Irbesartan and diuretics |
CO-IRBESSO |
Film coated tablet |
300 mg/ 12,5 mg |
|
30 |
Чайкафарма Висококачествените лекарства АД, България |
1 |
tabl |
- |
56.02 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 199/ 20.09.2011; |
02.11.2018 |
08.09.2012 |
|
Активен |
1075 |
| C09DA04 |
Irbesartan and diuretics |
CO-IRBESSO |
Film coated tablet |
150 mg/ 12,5 mg |
|
30 |
Чайкафарма Висококачествените лекарства АД, България |
1 |
tabl |
- |
38.53 |
0.24758 |
7.43 |
50% |
3.71 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 199/ 20.09.2011 |
02.07.2018 |
08.09.2012 |
|
Активен |
1074 |
| C09DA04 |
Irbesartan and diuretics |
Converide |
Film coated tablet |
300 mg/12,5 mg |
mg |
30 |
Medochemie Ltd., Кипър |
1 |
tabl |
- |
11.38 |
0.37933 |
11.38 |
50% |
5.69 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-5410/07.01.2015; НСР-12503/28.04.2017 г.; НСР-14041/02.10.2017 |
02.11.2017 |
|
|
Заличен |
3497 |
| C09DA04 |
Irbesartan and diuretics |
Converide |
Film coated tablet |
300 mg/12,5 mg |
|
14 |
Medochemie Ltd., Кипър |
1 |
tabl |
- |
14.32 |
0.32767 |
4.59 |
50% |
2.29 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-12948/08.06.2017 |
02.11.2018 |
|
|
Активен |
15751 |
| C09DA04 |
Irbesartan and diuretics |
CONVERIDE |
Film coated tablet |
150 mg/12.5 mg |
|
14 |
Medochemie Ltd., Кипър |
1 |
tabl |
- |
9.83 |
0.24758 |
3.47 |
50% |
1.73 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-15015/08.02.2018 |
02.07.2018 |
|
|
Активен |
16029 |
| C09DA04 |
Irbesartan and diuretics |
Irprezide |
Film coated tablet |
300 mg/12,5 mg |
mg |
30 |
Actavis Group PTC ehf., Исландия |
1 |
tabl |
- |
9.83 |
0.32767 |
9.83 |
50% |
4.91 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
КЦРР-1869/15.12.2012 г.; НСР-8335/26.02.2016.; HCP-8670/06.04.2016.; КП-71/17.09.2018 и НСР-15816/08.06.2018 |
02.11.2018 |
|
|
Активен |
1489 |